


Jim,
MYCAPSSA
patient



Prior Authorization and Access Guide

Visit chiesitotalcare.com
or call 1-833-346-2277
We're ready to help!

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE

MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

CONTRAINDICATIONS


Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.



Chiesi Total CareSM (CTC) will submit for insurance reimbursement and help you navigate prior authorization (PA).

Here's a step-by-step look at the process



PA denied? Chiesi Total Care is here to help.

It's not uncommon for the first PA submission to be denied. With a long track record of success in gaining PA and appeal approvals, Chiesi Total Care is here to provide assistance with the appeal process. Chiesi Total Care will assist in providing additional resources and/or publications depending on the reasons for denial. To request a copy of an additional resource or publication, please reach out directly to us.medical@chiesi.com.

Visit chiesitotalcare.com or call 1-833-346-2277



We provide updates on your patient's therapy and alert the office should there be any concerns. We also support patients by helping them cope with side effects and answering questions.

We can help by:

- Alerting when to refill or when refills are being missed
- Counseling patients on managing side effects
- Providing 24/7 pharmacist access
- Enrolling patients in the MYCAPSSA Copay Program – patients may pay as little as \$0 if eligible[‡]



[‡] Please refer to the full Terms and Conditions in the back pocket for additional eligibility requirements.

Lesa, Chiesi Total Care pharmacist

Here is a checklist of best practices for Prior Authorization submission:

- Include pertinent clinical notes, dates, and laboratory findings
- Include medical rationale for why the patient cannot use preferred formulary drugs
- Include prescribing practitioner NPI number and contact information
- Include therapeutic alternatives that were tried in the past

Important Safety Information

Drug interactions

The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women taking an oral contraceptive to use an alternative non-hormonal method of contraception or a back-up method when taking MYCAPSSA.

Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.



If you have questions, visit chiesitotalcare.com
or call 1-833-346-2277 – we're ready to help!

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE

MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

CONTRAINDICATIONS

Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.

WARNINGS AND PRECAUTIONS

MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.

Blood sugar, thyroid levels, and vitamin B₁₂ levels should be monitored and treated accordingly.

Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

ADVERSE REACTIONS

The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.

DRUG INTERACTIONS

The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women taking an oral contraceptive to use an alternative non-hormonal method of contraception or a back-up method when taking MYCAPSSA.

Patients taking proton pump inhibitors, H₂-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.

PREGNANCY

Advise premenopausal females of the potential for an unintended pregnancy.

To report SUSPECTED ADVERSE REACTIONS, please contact Chiesi Farmaceutici S.p.A. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

For more information, visit mycapssa.com.

Chiesi Total CareSM Program offered through AcariaHealth Specialty Pharmacy.

© 2024 CHIESI USA.

MYCAPSSA[®] is a registered trademark owned by the Chiesi Group.

Chiesi Total CareSM is a service mark of CHIESI FARMACEUTICI S.p.A.

PP-MC-0003 V1.0 2024

